iSpecimen Inc (ISPC)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $1.66M
Last updated: Nov 17, 2026 at 11:04 AM ET
iSpecimen Inc (ISPC) Competitors
The companies most similar to iSpecimen are bioAffinity Technologies (BIAF), XWELL (XWEL) and Exagen (XGN). By market cap, iSpecimen ranks 12th of the 13 companies on this page; Exagen (XGN) is the largest at $105.37M.
Peer Comparison
ISPC's revenue growth of -78.7% is below the peer median of -3.5%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| iSpecimen (ISPC) | $1.66M | N/A | 1.8x | 0.0% | N/A | -78.7% | 0.00% |
| bioAffinity Technologies, Inc. (BIAF) | $4.00M | N/A | 0.3x | -278.9% | -376.1% | -26.0% | 0.00% |
| XWELL Inc. (XWEL) | $5.62M | N/A | 0.2x | -82.9% | N/A | -7.1% | 0.00% |
| Exagen Inc (XGN) | $105.37M | N/A | 1.3x | -25.1% | -40.4% | 6.8% | 0.00% |
| Silexion Therapeutics Corp (SLXN) | $1.29M | N/A | 5.9x | 0.0% | N/A | 0.0% | 0.00% |
| VivoSim Labs, Inc. (VIVS) | $2.58M | N/A | 15.1x | 0.0% | N/A | -51.4% | 0.00% |
| BioRestorative Therapies Inc (BRTX) | $2.06M | N/A | 70.3x | 0.0% | -289.9% | -7.3% | 0.00% |
| MDxHealth SA (MDXH) | $13.75M | N/A | N/A | -38.3% | -40.5% | -17.2% | 0.00% |
| Precipio Inc (PRPO) | $39.68M | N/A | 1.3x | -4.1% | -5.7% | 8.3% | 0.00% |
| Revelation Biosciences Inc (REVB) | $2.43M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Enlivex Therapeutics Ltd (ENLV) | $1.82M | N/A | N/A | 0.0% | -0.3% | 0.0% | 0.00% |
| Calidi Biotherapeutics Inc. (CLDI) | $2.29M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Curis Inc (CRIS) | $2.97M | N/A | 1.6x | 0.0% | N/A | -66.0% | 0.00% |
| Peer median | $2.78M | N/A | 1.4x | 0.0% | -40.5% | -3.5% | 0.00% |
Similar Companies
These are the 12 companies most similar to iSpecimen, ranked by how closely their business, size, sector and industry match. The largest group, 7 of the 12, is in Biotechnology; the other 5 are in Diagnostics & Research.
| Company | About | Peers |
|---|---|---|
| bioAffinity Technologies, Inc. (BIAF)Diagnostics & Research | bioAffinity Technologies, Inc., a biotechnology company, is engaged in the development of non-invasive diagnostic tests and specific treatments for cancer. | BIAF competitors |
| XWELL Inc. (XWEL)Diagnostics & Research | XWELL Inc., a health and wellness services company, provides spa services at airports. The company is headquartered in New York, New York. | XWEL competitors |
| Exagen Inc (XGN)Diagnostics & Research | Exagen Inc. develops and markets various test products based on its Cell-Bound Complement Activation Products technology under the AVISE brand name... | XGN competitors |
| Silexion Therapeutics Corp (SLXN)Biotechnology | Biomotion Sciences (SLXN) is a forward-thinking biotechnology firm specializing in regenerative medicine... | SLXN competitors |
| VivoSim Labs, Inc. (VIVS)Biotechnology | VivoSim Labs, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. | VIVS competitors |
| BioRestorative Therapies Inc (BRTX)Biotechnology | BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue... | BRTX competitors |
| MDxHealth SA (MDXH)Diagnostics & Research | MDxHealth SA is a prominent biotechnology company focused on precision diagnostics that enhance cancer management, particularly in prostate and bladder cancers. | MDXH competitors |
| Precipio Inc (PRPO)Diagnostics & Research | Precipio, Inc., a cancer diagnostic and reagent technology company, provides diagnostic products and services in the United States oncology market. | PRPO competitors |
| Revelation Biosciences Inc (REVB)Biotechnology | Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of immunological diagnostics and therapeutics... | REVB competitors |
| Enlivex Therapeutics Ltd (ENLV)Biotechnology | Enlivex Therapeutics Ltd. is a clinical stage immunotherapy company. The company is headquartered in Nes Ziona, Israel. | ENLV competitors |
| Calidi Biotherapeutics Inc. (CLDI)Biotechnology | Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. | CLDI competitors |
| Curis Inc (CRIS)Biotechnology | Curis, Inc., a biotechnology company, is dedicated to the discovery and development of drug candidates for the treatment of human cancers in the United States. | CRIS competitors |
Frequently Asked Questions About ISPC
Who are iSpecimen's main competitors?
The companies most similar to iSpecimen include bioAffinity Technologies (BIAF), XWELL (XWEL), Exagen (XGN), Silexion Therapeutics (SLXN) and VivoSim Labs (VIVS), listed from the closest match.
Who is iSpecimen's biggest competitor?
Exagen (XGN) is the largest of the similar companies at $105.37M; bioAffinity Technologies (BIAF) is the closest match by business profile, size, sector and industry.
How does ISPC stock compare with its competitors?
ISPC's P/S is 1.8x against a peer median of 1.4x; its net margin is 0.0% against a peer median of 0.0%.
Which of iSpecimen's competitors pays a higher dividend?
iSpecimen pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is iSpecimen bigger than its competitors?
No. iSpecimen is 12th by market cap among the 13 companies on this page; the largest is Exagen (XGN) at $105.37M.
ISPC pages: Overview, Earnings, Financials, Competitors